ProCE Banner Activity

An Expert’s Guide to ASH 2024: Preview of the Top Abstracts

Conference Coverage
Clinical Thought

Experts highlight key studies being presented at the upcoming 2024 ASH Annual Meeting and Exposition. CCO’s Independent Conference Coverage will include timely summaries and practical implications of the latest research and developments in hematology to help you stay at the forefront of advances in cancer care.

Released: December 05, 2024

Expiration: December 04, 2025

Share

Faculty

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Catherine M. Broome

Catherine M. Broome, MD

Professor of Medicine
MedStar Georgetown University Hospital
Lombardi Cancer Center
Washington, DC

Jonathon B. Cohen

Jonathon B. Cohen, MD, MS

Professor, Hematology and Medical Oncology
Emory University – Winship Cancer Institute
Atlanta, Georgia

Corey Cutler

Corey Cutler, MD, MPH

Director, Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Courtney DiNardo

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Rami Komrokji

Rami Komrokji, MD

Vice Chair of Malignant Hematology Department
Senior Member and Professor of Oncologic Sciences
H. Lee Moffitt Cancer Center
University of South Florida
Tampa, Florida

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Noopur Raje

Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Eytan M. Stein

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Amer Zeidan

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Cellectar, Foresight Diagnostics, Genentech, Gilead, Interius, Roche; researcher: Bristol Myers Squibb, Celgene, Cellectis, Genentech, Merck, Mustang Bio, Regeneron, Seagen, Takeda.

Catherine M. Broome, MD

Professor of Medicine
MedStar Georgetown University Hospital
Lombardi Cancer Center
Washington, DC

Catherine M. Broome, MD: consultant/advisor/speaker: Alexion, Sanofi, researcher: Alpine, Novartis.

Jonathon B. Cohen, MD, MS

Professor, Hematology and Medical Oncology
Emory University – Winship Cancer Institute
Atlanta, Georgia

Jonathon Cohen, MD: consultant/advisor/speaker: AstraZeneca, ADCT, Beigene, Genentech, HutchMed, Janssen, Kite/Gilead, Loxo/Lilly; researcher: AstraZeneca, Bristol-Myers Squibb/Celgene, Genentech, Loxo/Lilly, Novartis, Takeda.

Corey Cutler, MD, MPH

Director, Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Corey Cutler, MD, MPH: consultant/advisor/speaker: CareDx, Cimeio, CSL Behring, Incyte, OrcaBio, Oxford Immune Algorithmics, Sanofi, Syndax; publicly traded stock/stock options: Cimeio, OrcaBio, Oxford Immune Algorithmics.

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Courtney DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Rigel, Servier, Schrodinger.

Rami Komrokji, MD

Vice Chair of Malignant Hematology Department
Senior Member and Professor of Oncologic Sciences
H. Lee Moffitt Cancer Center
University of South Florida
Tampa, Florida

Rami Komrokji, MD: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, DSI, Genentech, Geron, Jazz, PharmaEssentia, Rigel, Servier, Sobi, Sumitomo; researcher: Bristol Myers Squibb.

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD: advisor: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; other financial or material support: TG Therapeutics.

Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor: AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, Genentech, GlaxoSmithKline, Immuneel, Johnson & Johnson, Pfizer, Regeneron, Sanofi.

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan Stein, MD: consultant/advisor/speaker: AbbVie, Agios, Aptose, Astellas, Blueprint, Bristol Myers Squibb, Calithera, CTI Biopharma, Daiichi Sankyo, Foghorn, Genentech, Genesis, Gilead, Janssen, Jazz Pharmaceuticals, Kura, Menarini, Neoleukin, Novartis, OnCusp, Ono Pharma, PinotBio, Servier, Syndax, Syros; data and safety monitoring board: Cellectis, Epizyme; researcher: Bristol Myers Squibb, Eisai; stock/stock options: Auron.

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer M. Zeidan, MBBS, MHS: researcher (paid to institution): AbbVie, Aprea, Astex, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Cura, Foran, Geron, Incyte, Kura, MedImmune/AstraZeneca, Novartis, Pfizer, Shattuck Labs, Takeda; consultant/advisor/speaker: AbbVie, Agios, ALX Oncology, Amgen, Astellas, BeyondSpring, BioCryst, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Chiesi, Daiichi Sankyo, Epizyme, Genentech, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Seattle Genetics, Schrodinger, Servier, Syndax, Syros, Taiho, Takeda, Tyme, Zentalis; other financial or material support: AbbVie, ALX Oncology, BioCryst, Celgene/Bristol Myers Squibb, Geron, Gilead, Kura, Novartis, Syros.